Stockreport

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program [Yahoo! Finance]

Vir Biotechnology, Inc.  (VIR) 
PDF – Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts – – Combination well-tolerated: no trea [Read more]